192 related articles for article (PubMed ID: 36422101)
21. Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome.
Basel D; Mosheva M; Maeder J; Schneider M; Shani S; Weinberger R; Eliez S; Gothelf D
Eur Child Adolesc Psychiatry; 2022 Sep; 31(9):1367-1375. PubMed ID: 33871687
[TBL] [Abstract][Full Text] [Related]
22. Face processing in 22q11.2 deletion syndrome: atypical development and visual scanning alterations.
Zaharia A; Schneider M; Glaser B; Franchini M; Menghetti S; Schaer M; Debbané M; Eliez S
J Neurodev Disord; 2018 Aug; 10(1):26. PubMed ID: 30157749
[TBL] [Abstract][Full Text] [Related]
23. Attention Deficit Hyperactivity Disorder Symptoms and Psychosis in 22q11.2 Deletion Syndrome.
Niarchou M; Calkins ME; Moore TM; Tang SX; McDonald-McGinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
Schizophr Bull; 2018 Jun; 44(4):824-833. PubMed ID: 29040797
[TBL] [Abstract][Full Text] [Related]
24. Testing criteria for 22q11.2 deletion syndrome: preliminary results of a low cost strategy for public health.
Sgardioli IC; Paoli Monteiro F; Fanti P; Paiva Vieira T; Gil-da-Silva-Lopes VL
Orphanet J Rare Dis; 2019 Jun; 14(1):123. PubMed ID: 31159889
[TBL] [Abstract][Full Text] [Related]
25. Candidate modifier genes for immune function in 22q11.2 deletion syndrome.
Pinnaro CT; Henry T; Major HJ; Parida M; DesJardin LE; Manak JR; Darbro BW
Mol Genet Genomic Med; 2020 Jan; 8(1):e1057. PubMed ID: 31830774
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review.
Mosheva M; Korotkin L; Gur RE; Weizman A; Gothelf D
Eur Child Adolesc Psychiatry; 2020 Aug; 29(8):1035-1048. PubMed ID: 30949827
[TBL] [Abstract][Full Text] [Related]
27. Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome.
Monks S; Niarchou M; Davies AR; Walters JT; Williams N; Owen MJ; van den Bree MB; Murphy KC
Schizophr Res; 2014 Mar; 153(1-3):231-6. PubMed ID: 24534796
[TBL] [Abstract][Full Text] [Related]
28. [22q11.2DS Syndrome as a Genetic Subtype of Schizophrenia].
Huertas-Rodríguez CK; Payán-Gómez C; Forero-Castro RM
Rev Colomb Psiquiatr; 2015; 44(1):50-60. PubMed ID: 26578219
[TBL] [Abstract][Full Text] [Related]
29. Identifying patterns of anxiety and depression in children with chromosome 22q11.2 deletion syndrome: comorbidity predicts behavioral difficulties and impaired functional communications.
Stephenson DD; Beaton EA; Weems CF; Angkustsiri K; Simon TJ
Behav Brain Res; 2015 Jan; 276():190-8. PubMed ID: 24906195
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of miR-185 is a common pathogenic event in 22q11.2 deletion syndrome-related and idiopathic schizophrenia.
Sabaie H; Gharesouran J; Asadi MR; Farhang S; Ahangar NK; Brand S; Arsang-Jang S; Dastar S; Taheri M; Rezazadeh M
Metab Brain Dis; 2022 Apr; 37(4):1175-1184. PubMed ID: 35075501
[TBL] [Abstract][Full Text] [Related]
31. [22q11.2 microdeletion syndrome: Analysis of the care pathway before the genetic diagnosis].
Ingrao T; Lambert L; Valduga M; Bosser G; Albuisson E; Leheup B
Arch Pediatr; 2017 Nov; 24(11):1067-1075. PubMed ID: 28967605
[TBL] [Abstract][Full Text] [Related]
32. Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia.
Van L; Boot E; Bassett AS
Curr Opin Psychiatry; 2017 May; 30(3):191-196. PubMed ID: 28230630
[TBL] [Abstract][Full Text] [Related]
33. Exploring the potential association among sleep disturbances, cognitive impairments, and immune activation in 22q11.2 deletion syndrome.
Yirmiya ET; Mekori-Domachevsky E; Weinberger R; Taler M; Carmel M; Gothelf D
Am J Med Genet A; 2020 Mar; 182(3):461-468. PubMed ID: 31837200
[TBL] [Abstract][Full Text] [Related]
34. Identification of a DNA Methylation Episignature in the 22q11.2 Deletion Syndrome.
Rooney K; Levy MA; Haghshenas S; Kerkhof J; Rogaia D; Tedesco MG; Imperatore V; Mencarelli A; Squeo GM; Di Venere E; Di Cara G; Verrotti A; Merla G; Tedder ML; DuPont BR; Sadikovic B; Prontera P
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445317
[TBL] [Abstract][Full Text] [Related]
35. Thymic and bone marrow output in individuals with 22q11.2 deletion syndrome.
Dar N; Gothelf D; Korn D; Frisch A; Weizman A; Michaelovsky E; Carmel M; Yeshayahu Y; Dubnov-Raz G; Pessach IM; Simon AJ; Lev A; Somech R
Pediatr Res; 2015 Apr; 77(4):579-85. PubMed ID: 25580739
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA Dysregulation, Gene Networks, and Risk for Schizophrenia in 22q11.2 Deletion Syndrome.
Merico D; Costain G; Butcher NJ; Warnica W; Ogura L; Alfred SE; Brzustowicz LM; Bassett AS
Front Neurol; 2014; 5():238. PubMed ID: 25484875
[TBL] [Abstract][Full Text] [Related]
37. A comparative study of the neuropsychiatric and neurocognitive phenotype in two microdeletion syndromes: velocardiofacial (22q11.2 deletion) and Williams (7q11.23 deletion) syndromes.
Zarchi O; Diamond A; Weinberger R; Abbott D; Carmel M; Frisch A; Michaelovsky E; Gruber R; Green T; Weizman A; Gothelf D
Eur Psychiatry; 2014 May; 29(4):203-10. PubMed ID: 24054518
[TBL] [Abstract][Full Text] [Related]
38. 22q11.2 duplication syndrome: elevated rate of autism spectrum disorder and need for medical screening.
Wenger TL; Miller JS; DePolo LM; de Marchena AB; Clements CC; Emanuel BS; Zackai EH; McDonald-McGinn DM; Schultz RT
Mol Autism; 2016; 7():27. PubMed ID: 27158440
[TBL] [Abstract][Full Text] [Related]
39. Molecular screening for 22Q11.2 deletion syndrome in patients with congenital heart disease.
Huber J; Peres VC; de Castro AL; dos Santos TJ; da Fontoura Beltrão L; de Baumont AC; Cossio SL; Dalberto TP; Riegel M; Cañedo AD; Schaan BD; Pellanda LC
Pediatr Cardiol; 2014 Dec; 35(8):1356-62. PubMed ID: 24880467
[TBL] [Abstract][Full Text] [Related]
40. Reproductive Health Issues for Adults with a Common Genomic Disorder: 22q11.2 Deletion Syndrome.
Chan C; Costain G; Ogura L; Silversides CK; Chow EW; Bassett AS
J Genet Couns; 2015 Oct; 24(5):810-21. PubMed ID: 25579115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
